Page 232 - Programme book for The International Liver Congress 2015, EASL ILC 2015
P. 232
Viral Hepatitis: Hepatitis B & D - Clinical (Therapy, New Compounds, Resistance) (Cont.)
P0648 LONG-TERM OUTCOME OF CHEMOTHERAPY-INDUCED
HBV REACTIVATION IN LYMPHOMA PATIENTS WITH
RESOLVED HBV INFECTION
Hung-Chih Yang, Hsiao-Hui Tsou, Mei-Hsing Chuang, Chi-Ling Chen,
Tsang-Wu Liu, Pei-Jer Chen, Ann-Lii Cheng, Chiun Hsu*, Taiwan
P0649 CHARACTERIZATION OF HBSAG LOSS IN PATIENTS
WITH CHRONIC HEPATITIS B (CHB) TREATED WITH
NUCLEOS/TIDE ANALOGS (NUCS): A RETROSPECTIVE
MULTICENTER STUDY (HEBESAS)
Emilio Suárez*, Miguel A. Simón, María Buti, Martín Prieto,
Juan M. Pascasio, Manuel Rodríguez, Teresa Casanovas, Javier Crespo,
Juan Arenas, Rafael Gómez, Blanca Figueruela, Moisés Diago,
Rosa Morillas, José M. Zozaya, José L. Calleja, Marta Casado,
Esther Molina, Javier Fuentes, Spain
P0650 RENAL AND BONE EVENTS IN PATIENTS WITH CHRONIC
HEPATITIS B RECEIVING LONG-TERM ORAL NUCLEOS(T)
ePOSTERS IDE ANALOGUE TREATMENT – A STUDY OF 53,500
SUBJECTS
Grace L. Wong*,Yee-Kit Tse, Vincent W. Wong,
Terry Y. Fung, Henry L. Chan, Hong Kong, China
P0651 CLINICAL OUTCOME AND PREDICTOR FOR RELAPSE
AFTER CESSATION OF ORAL ANTIVIRAL TREATMENT
IN CHRONIC HEPATITIS B PATIENTS: A PROSPECTIVE
OBSERVATIONAL COHORT STUDY
Kyu Sik Jung*, Jun Yong Park,Young Eun Chon, Hyon-Suk Kim,
Wonseok Kang, Seung Up Kim, Beom Kyung Kim, Do Young Kim,
Kwang-Hyub Han, Sang Hoon Ahn, South Korea
P0652 EFFECT OF TENOFOVIR ON KEY HEPATITIS B VIRUS
MARKERS IN PREGNANT WOMEN DURING THE THIRD
TRIMESTER AND POSTPARTUM
Kathy Jackson, Lilly Yuen, Vi Nguyen, Julianne Bayliss*,
Stephen Locarnini, Miriam Levy, Australia
P0653 PERFORMANCE EVALUATION OF THE UPDATED ELECSYS
ANTI-HBS II IMMUNOASSAY
Annelies Mühlbacher, Stefan Böhm, Volkmar Schottstedt,
Nattiya Hirankarn, Sunida K. Vandelaer, Andreas Woeste*, Germany
232 The International Liver Congress™ 2015 • ILC Programme
P0648 LONG-TERM OUTCOME OF CHEMOTHERAPY-INDUCED
HBV REACTIVATION IN LYMPHOMA PATIENTS WITH
RESOLVED HBV INFECTION
Hung-Chih Yang, Hsiao-Hui Tsou, Mei-Hsing Chuang, Chi-Ling Chen,
Tsang-Wu Liu, Pei-Jer Chen, Ann-Lii Cheng, Chiun Hsu*, Taiwan
P0649 CHARACTERIZATION OF HBSAG LOSS IN PATIENTS
WITH CHRONIC HEPATITIS B (CHB) TREATED WITH
NUCLEOS/TIDE ANALOGS (NUCS): A RETROSPECTIVE
MULTICENTER STUDY (HEBESAS)
Emilio Suárez*, Miguel A. Simón, María Buti, Martín Prieto,
Juan M. Pascasio, Manuel Rodríguez, Teresa Casanovas, Javier Crespo,
Juan Arenas, Rafael Gómez, Blanca Figueruela, Moisés Diago,
Rosa Morillas, José M. Zozaya, José L. Calleja, Marta Casado,
Esther Molina, Javier Fuentes, Spain
P0650 RENAL AND BONE EVENTS IN PATIENTS WITH CHRONIC
HEPATITIS B RECEIVING LONG-TERM ORAL NUCLEOS(T)
ePOSTERS IDE ANALOGUE TREATMENT – A STUDY OF 53,500
SUBJECTS
Grace L. Wong*,Yee-Kit Tse, Vincent W. Wong,
Terry Y. Fung, Henry L. Chan, Hong Kong, China
P0651 CLINICAL OUTCOME AND PREDICTOR FOR RELAPSE
AFTER CESSATION OF ORAL ANTIVIRAL TREATMENT
IN CHRONIC HEPATITIS B PATIENTS: A PROSPECTIVE
OBSERVATIONAL COHORT STUDY
Kyu Sik Jung*, Jun Yong Park,Young Eun Chon, Hyon-Suk Kim,
Wonseok Kang, Seung Up Kim, Beom Kyung Kim, Do Young Kim,
Kwang-Hyub Han, Sang Hoon Ahn, South Korea
P0652 EFFECT OF TENOFOVIR ON KEY HEPATITIS B VIRUS
MARKERS IN PREGNANT WOMEN DURING THE THIRD
TRIMESTER AND POSTPARTUM
Kathy Jackson, Lilly Yuen, Vi Nguyen, Julianne Bayliss*,
Stephen Locarnini, Miriam Levy, Australia
P0653 PERFORMANCE EVALUATION OF THE UPDATED ELECSYS
ANTI-HBS II IMMUNOASSAY
Annelies Mühlbacher, Stefan Böhm, Volkmar Schottstedt,
Nattiya Hirankarn, Sunida K. Vandelaer, Andreas Woeste*, Germany
232 The International Liver Congress™ 2015 • ILC Programme
